Rakuten on February 26
BeiGene***A-shares**:688235, Hong Kong stocks**:06160, U.S. stocks**:BGNE) today released its 2023 annual results report, which showed that BeiGene's revenue in 2023 was 1742.3 billion yuan, up from 9.5 billion in the same period last year6.6 billion yuan, an increase of 821%。
Among them, BeiGene's product revenue in 2023 is 1550.4 billion yuan, compared with 84.4 in the same period last year800 million yuan, an increase of 828%, the increase in product revenue was mainly due to the increase in product sales in the company's core markets.
In 2023, BRUKINSA global sales totaled 913.8 billion yuan, with global sales totaling 382.9 billion yuan, a year-on-year increase of 1387%, further consolidating its leadership position in the field of hematological oncology. At present, all five indications approved by BRUKINSA in China have been included in the National Catalogue of Drugs for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance ("National Medical Insurance Catalogue").
In 2023, the sales of tislean totaled 380.6 billion yuan, with sales totaling 285.9 billion yuan, a year-on-year increase of 331%。At present, tislelizumab has been approved for 1 indication in the European Union and the United Kingdom, and 12 indications in China, of which 11 indications have been included in the national medical insurance catalog.
BeiGene's 2023 operating loss was 88100 million yuan, compared with an operating loss of 134 in the same period last year$2.5 billion; The net loss was 671.6 billion yuan, compared with a net loss of 136 in the same period last year400 million yuan; The net loss after deducting non-profits was 96800 million yuan, and the net loss after deducting non-profits in the same period last year was 138$2.4 billion.
Lei Di was founded by ** Lei Jianping, if ** please in**.